ABCL earnings analysis
What we found in ABCL's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
AbCellera reported a strong Q1 2026, with revenue of $8.3 million and an EPS of -$0.14, outpacing estimates. This marks a significant recovery from prior quarters, attributed to advancements in its research programs and a robust liquidity position. However, ongoing operating losses and high R&D expenses continue to pose challenges.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Significant Revenue Growth
- Q1 2026 revenue increased by 96% year-over-year to $8.3 million compared to $4.2 million in Q1 2025.
- EPS Surprise
- Reported EPS of -$0.14 beat expectations of -$0.20 by a margin of $0.06.
- Robust Liquidity Position
- Liquidity stands at $504.7 million, including $77.1 million in cash and cash equivalents.
- Decreased Operating Expenses
- Total operating expenses fell slightly to $65.8 million from $66.9 million year-over-year.
- Improved Gross Margin
- Gross margin for Q1 2026 was 100%, consistent with previous quarters.
- Positive Phase 1 Data
- Recent positive Phase 1 clinical trial data for ABCL635 indicates effective treatment with a favorable safety profile.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Operating Losses
- Operating loss decreased to $57.5 million in Q1 2026, but losses persist as R&D expenses rose to $46.7 million.
- High R&D Expenses
- Research and development expenses increased by 10% year-over-year to $46.7 million, raising concerns about sustainability.
- Market Reliance on Clinical Trials
- The company's future success heavily depends on the outcomes of ongoing clinical trials, particularly for ABCL635.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.14
- Gross margin
- 100.0%
What they said about what is next.
Guidance deferred to earnings press release / call.
The filing reads better than the one before it.
What came before.
- 10-K · February 24, 2026
- AbCellera completed its multi‑year platform build in 2025, opened a 130,000‑square‑foot clinical manufacturing facility and transitioned to an internal, clinical‑stage pipeline (two clinical candidates and two…
- 10-Q · August 7, 2025
- AbCellera reported Q2 revenue of $17,084,000 (up from $7,323,000 in Q2 2024) and GAAP diluted loss per share of $(0.12). Revenue strength was driven by a $10,445,000 licensing revenue recognition; operating loss…
- 10-Q · November 4, 2024
- AbCellera reported Q3 (three months ended September 30, 2024) revenue of $6,507,000 and GAAP diluted loss per share of $(0.17). Revenue was roughly flat year-over-year (Q3 2023: $6,599,000) while operating loss widened…
- 10-Q · May 7, 2024
- AbCellera reported quarterly revenue of $9.954 million and GAAP net loss per share of $(0.14). Revenue declined from $12.192 million a year earlier while operating expenses fell (total operating expenses $64.848…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ABCL makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever